Fig. 5.

Effect of pharmacological targeting of CysLT₂R with BayCysLT₂. (A–K) LLC cells (2 × 10⁶ in 100 μL of PBS) were injected s.c. into both flanks of 6- to 8-wk-old WT mice. When tumors were palpable on the seventh day, mice were randomized into two groups. One group was injected (i.p.) with 3 mg/kg of Bay (n = 10; BayCysLT₂), and the other group was injected with saline (n = 10) as a vehicle control every other day (five doses). On day 21 after tumor transplantation, mice were injected with Texas Red-conjugated dextran 20 min before euthanasia. Treatment with BayCysLT₂ inhibits tumor volume (A–C), metastasis to the lung (D and E), and metastatic area (F). (Scale bars: 200 μm.) (G) Immunofluorescence images of tumor sections showing pericyte coverage (CD31/NG2 staining, Upper) and leakage of Texas (TX) Red-conjugated dextran (Lower). (Scale bars: 100 μm.) Quantification of vessel density (H), pericyte coverage (I), and leakage of TX Red-conjugated dextran (J) are shown. (K) Immunofluorescence images of tumor sections showing CD45⁺ cells infiltrating the tumor (CD31, green; DAPI, blue). (Scale bars: 100 μm.) Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 determined by the Mann–Whitney U test.